"Of thinking to precisely on th’ event –A thought which,...

"Of thinking to precisely on th’ event –

A thought which, quarter’d, hath but one part wisdom

And ever three part coward –"

Hamlet

William Shakespeare

My Friends,

It would be remiss of Tiresias not to comment on this past week's price action, possible causes, and consequences. Tiresias has no doubts that Opti scan has one of the most exciting, revolutionary, and disruptive technologies in medical imaging today. Optiscan’s Confocal Laser Endomicroscopy (CLE) will transform pathology, and revolutionise cancer screening, cancer surgery, and cancer treatment. CLE will enable real-time pathology, in vivo, in the clinic and in the operating room. It will enable real-time digital biopsy, with real-time instantaneous expert pathological diagnosis to anyone, anywhere in the world at any time. As a small window into the future of which Tiresias is seeing, and although it may be a little arcane for his many non-medical friends, Tiresias suggests they look at Carl Zeiss’s new notice, for the 2ND ZEISS CONVIVO Clinical Symposium, scheduled for 23rd June 2021. This symposium is on in vivo real-time pathology in neurosurgery. It will be an update of the latest scientific findings, developments, and new enhancements to in vivo real-time pathology. As Tiresias has pointed out before, this is just the beginning of transformation centralisation of expert pathological consultation for histopathology in real time. Carl Zeiss is using neurosurgery as the test bed, and applications in other fields, the “low hanging fruit”, oral screening and surgery, gastrointestinal, skin, breast and cervix are under way.

So, what about the price action? The market is usually looking forward, but occasionally also looks back at times, and sometimes in fright. Naturally, looking back, and those with long memories of Optiscan looks back and have a little nervous twitch. The share price of Optiscan has recently gone up a bit. Then came this week’s little update. To the long-term term holders and the traders sitting nervously on paper gains, it brought back a few less than happy memories. Is this still the same Optiscan? Has Optiscan really changed? Can a leopard change its spots? Is this the same thing all over again? “Déjà vu all over again”?

Tiresias is confident the recent changes in Optiscan are real, are transformative, and not just cosmetic. The company is capitalised with very strong backing of backers with vision and understanding. There is a great strengthening in the management. The technology is still there and is real. This pullback is a healthy testing of the holders, to shake out the weak hands, before the resumption of its rise to match its true value. Tiresias muses that, if Optiscan did not have its history: if Optiscan was an IPO this week: if it was explained properly to the wider market and institution: if the impact of its technology was understood: the stock price would be heading to 10 X or 20 X of its present price. Tiresias says buy the dips and never sell.